-
Brit J Cancer: Relationship between antibiotic use and colorectal cancer risk.
Time of Update: 2020-10-04
There have been no studies to report a correlation between oral antibiotics and colorectal cancer (CRC) that varies with the antibiotic spectrum and colorectal cancer type, and whether there is a nonlinear dose-dependent relationship.
the correlation between antibiotic use and CRC risk appears to vary between broad-spectrum and narrow-spectrum antibiotics.
-
NEJM: Oghidini as an EGFR mutation-positive NSCLC postoperative auxiliary therapy, patients significantly benefit.
Time of Update: 2020-10-04
Data updated by 's hypothetical CNS and non-CNS recurrence rates ADAURA studies show that reduced risk of local and distant recurrence, as well as improvements in CNS DFS, further support for Oghidini-assisted therapy as an efficient, practice-changing treatment strategy for EGFR gene mutation-positive I.B.III.A NSCLC patients after tumor complete removal.
-
Medical College Oncology Hospital Zhang Wei: Don't think it's just an aid, it may affect the whole cancer war.
Time of Update: 2020-10-04
"The rate of nausea and vomiting is still relatively high during anti-tumor treatment, and I want more people to know that we already have a lot of good anti-spitting drugs and need to explore a more
-
Lancet oncol: The quality of life of metastatic despotic prostate cancer patients treated with kabatha.
Time of Update: 2020-10-04
In the CARD study, cabazitaxel (kabatasai) significantly extended the progression-free survival of patients with metastatic degenerative resistance prostate cancer treated with too much cyclocycline and androgen targeted inhibitors.
-
Brit J Cancer: New urine protein biomarker group for early diagnosis of stomach cancer.
Time of Update: 2020-10-04
in the training and validation queue, the urine biomarker groups of uTFF1, uADAM12 and Helicobacter pyridosis were combined to distinguish HC and GC patients significantly.
-
Lancet oncol: The long-term efficacy of postoperative ancillary therapy for the maintenance of high-risk melanoma is significantly better than that of Ipi monoanti.
Time of Update: 2020-10-04
4-year recurrence-free survival rates in the Navu monoantigroup and the Ipi monoantigroup were 51.7% and 41.2%, respectively (risk ratio of 0.71, 95% CI 0.60-0.86, p=0.0003).
-
Cell Death Dis: PLCɛ is critical to maintaining the function of AR signals in prostate cancer.
Time of Update: 2020-10-04
the study found that PLCɛ (phospholipidase C) was highly expressed in CaP samples, and that this high expression level was closely related to the activity of ar signal transduction path.
these effects eventually lead to the weakening of AR signals in CaP and inhibit AR-driven cell migration and invasion.
-
Nat Commun: French scientists have discovered a new drug-resistant treatment strategy for cancer immunotherapy.
Time of Update: 2020-10-04
study, the authors found that anti-GARP:TGF-beta-1mAb, in combined with PD-1 blockers, significantly enhanced the effects of tumor T cells and prevented tumor recurrence.
-
Clin Cancer Res: Antimalarial drug chloroquine increases the sensitivity of GNAQ/11 mutant melanoma to MEK1/2 inhibitors!
Time of Update: 2020-10-04
This study aims to evaluate the role of chloroquine (lysosome inhibitors, antimalarial drugs) or hydroxychloroquine combined MAP kinase pathps to inhibit the effects of GNAQ/11 mutant cells in and outside the body, and to clarify the mechanism of action of MEK1/2 inhibitors combined with chloroquine induced cytotoxicity.
-
Acta Neuropathologica: C11orf95-RELA reprogrammed the 3D epigenome of the on-screen chamber membrane tumor.
Time of Update: 2020-10-04
paper, the authors' team found that the C11orf95 component of the fusion protein determines DNA binding activity, while the RELA component is necessary to drive gene expression associated with tratermoblastoma.
-
Rongchang Bio-Virdixito monoanti (RC48) treatment of urethra skin cancer was recognized by the FDA breakthrough therapy.
Time of Update: 2020-10-04
the FDA's breakthrough therapy determination means that the clinical data of the new drug show significant efficacy compared to existing treatments, which will accelerate the process of clinical development and meet the needs of patients at an early time.
-
Real-world research has released the world's first cancer electric field treatment to benefit Chinese patients.
Time of Update: 2020-10-04
On September 12, 2020, at the 4th Annual Meeting and 4th China Cerebral Glioma Academic Conference of the Professional Committee of the Chinese Physicians Association, a forward-looking, one-arm obser
-
NEJM Heavyweight: 2 years in advance! Wu Yilong, in a team of 284 centers around the world and in China, found that surgery and precision-type targeted therapy reduced the risk of recurrence of early and mid-stage lung cancer by 83%.
Time of Update: 2020-10-04
In summary, the study found that in NSCLC patients who were positive for EGFR mutations in periods IB to IIIA, patients who received oxytinib had significantly longer disease-free survival than those who received placebo (for patients with early and mid-stage lung cancer from IB to IIIA with a drive gene mutation, their risk of tumor recurrence decreased by 83 percentage points after pre-surgical removal with the help of third-generation targeted drugs).
-
Terisha reduced the risk of brain recurrence by 82% in the early EGFR mutation lung cancer-assisted treatment.
Time of Update: 2020-10-04
A preset exploratory analysis of a Phase III ADAURA clinical study based on positive results showed that AstraZeneza's Terisa (chemical name: Ogini Osimertinib, trade name: Terisa Tagrisso) was in the early stages of undergoing a complete tumor excision (Complementary treatment in patients with non-small cell lung cancer (NSCLC) of EGFRm, a prefrontal growth factor change (EGFRm) in IB, II and IIIA periods, can lead to clinically significant improvements in the disease-free survival of the central nervous system (CNS) (DFS).
-
CA Cancer J Clin: Revealing the cruel truth that cancer is getting younger! The number of cancer cases among young people has been increasing in the last 10 years.
Time of Update: 2020-10-04
the age group 20-29, the incidence of cancer is 42 and 55 cases per 100,000 population, respectively, and the incidence of cancer among women is 30 per cent higher than that of men.
-
2020 CSCO Conference opens, wonderful non-stop!
Time of Update: 2020-10-04
Professor Wang Jie of the Oncology Hospital of the Chinese Academy of Medical Sciences interpreted the RATIONALE 307 study: a Phase III study of patients with advanced squamous non-small cell lung cancer treated with pure chemotherapy first-line chemotherapy, which was first published at this year's ASCO Conference and the latest results were presented at this year's ESMO Conference.
-
Clin Cancer Res: The efficacy of the second-generation yew-alkane Kabatsai treatment for metastatic stomach cancer.
Time of Update: 2020-10-04
(effects of HER2 state on the efficacy of kabatha) (effects of M2 macrophage characteristics on the efficacy of kabatha) HER2 amplification or over-expression was associated with increased course control, PFS, and overall survival.
-
J Vasc Surg: 20 years of single-center follow-up results, the first generation of stent cavity repair aneurysm overall results.
Time of Update: 2020-10-04
to explore the prognosis for the first generation of stent implants (Vanguard) to treat patients with abdominal aortic aneurysms (AAA), researchers from Finland shared the results of a 20-year follow-up at a single center.
-
CSCO 2020 Look: What's the busiest PI, do you know?
Time of Update: 2020-10-04
In the field of oncology in China, gastric cancer experts have "North Shen, South Li" Ya, "North Shen" refers to Professor Shen Lin of Peking University Cancer Hospital, "South Li" refers to The Shanghai Oriental Hospital well-known oncologist, former chairman of CSCO Professor Li Jin.
-
Nat Commun: Oghidini, in conjunction with drug-resistant signal suppression, significantly improves the prognosm of EGFR mutant lung cancer.
Time of Update: 2020-10-04
Map of the potential mechanisms by which oxytinib induces FOXA1 and IGF-1R expression The researchers found that cells with low expression levels of AXL were more sensitive to oxytinib than cells with high expression levels of AXL in EGFR mutant lung cancer (EGFRmut-LC) cells, but Ohithini resistance appeared in a small number of populations.
